Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1766, Issue 1, 2006, Pages 42-52

  Mikesch, Jan Henrik ^a   Buerger, Horst ^b   Simon, Ronald ^c   Brandt, Burkhard ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Decay accelerating factor

Indexed keywords

CANCER VACCINE; CD97 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE ANTIGEN; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SC 1; RITUXIMAB; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; COMPLEMENT SYSTEM; CYTOLYSIS; ENZYME ACTIVATION; HUMAN; IMMUNOMODULATION; LYMPH NODE METASTASIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOLECULAR WEIGHT; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD55; CELL ADHESION; CELL MOVEMENT; HUMANS; NEOPLASMS;

EID: 33746859405     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2006.04.001     Document Type: Review

References (153)

1. Hoffmann E.M. Inhibition of complement by a substance isolated from human erythrocytes-I. Immunochemistry 6 (1969) 391-403
2. Hoffmann E.M. Inhibition of complement by a substance isolated from human erythrocytes-II. Immunochemistry 6 (1969) 405-419
3. Nickells M.W., Alvarez J.I., Lublin D.M., and Atkinson J.P. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1. J. Immunol. 152 (1994) 676-685
4. Nonaka M., Miwa T., Okada N., Nonaka M., and Okada H. Multiple isoforms of guinea pig decay-accelerating factor (DAF) generated by alternative splicing. J. Immunol. 155 (1995) 3037-3048
5. Spicer A.P., Seldin M.F., and Gendler S.J. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J. Immunol. 155 (1995) 3079-3091
6. Hinchliffe S.J., Spiller O.B., Rushmere N.K., and Morgan B.P. Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J. Immunol. 161 (1998) 5695-5703
7. Kuttner-Kondo L., Subramanian V.B., Atkinson J.P., Yu J., and Medof M.E. Conservation in decay accelerating factor (DAF) structure among primates. Dev. Comp. Immunol. 24 (2000) 815-827
8. Perez de la Lastra J.M., Harris C.L., Hinchliffe S.J., Holt D.S., Rushmere N.K., and Morgan B.P. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats. J. Immunol. 165 (2000) 2563-2573
9. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., and Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129 (1982) 184-189
10. Kinoshita T., Medof M.E., Silber R., and Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 162 (1985) 75-92
11. Nicholson-Weller A., March J.P., Rosen C.E., Spicer D.B., and Austen K.F. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 65 (1985) 1237-1244
12. Asch A.S., Kinoshita T., Jaffe E.A., and Nussenzweig V. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J. Exp. Med. 163 (1986) 221-226
13. Medof M.E., Walter E.I., Rutgers J.L., Knowles D.M., and Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165 (1987) 848-864
14. Lublin D.M., Lemons R.S., Le Beau M.M., Holers V.M., Tykocinski M.L., Medof M.E., and Atkinson J.P. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J. Exp. Med. 165 (1987) 1731-1736
15. Post T.W., Arce M.A., Liszewski M.K., Thompson E.S., Atkinson J.P., and Lublin D.M. Structure of the gene for human complement protein decay accelerating factor. J. Immunol. 144 (1990) 740-744
16. Caras I.W., Davitz M.A., Rhee L., Weddell G., Martin Jr. D.W., and Nussenzweig V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325 (1987) 545-549
17. Lublin D.M., and Atkinson J.P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7 (1989) 35-58
18. Lukacik P., Roversi P., White J., Esser D., Smith G.P., Billington J., Williams P.A., Rudd P.M., Wormald M.R., Harvey D.J., Crispin M.D., Radcliffe C.M., Dwek R.A., Evans D.J., Morgan B.P., Smith R.A., and Lea S.M. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1279-1284
19. Nicholson-Weller A., and Wang C.E. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123 (1994) 485-491
20. Nakano Y., Sumida K., Kikuta N., Miura N.H., Tobe T., and Tomita M. Complete determination of disulfide bonds localized within the short consensus repeat units of decay accelerating factor (CD55 antigen). Biochim. Biophys. Acta 1116 (1992) 235-240
21. Brodbeck W.G., Liu D., Sperry J., Mold C., and Medof M.E. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156 (1996) 2528-2533
22. Coyne K.E., Hall S.E., Thompson S., Arce M.A., Kinoshita T., Fujita T., Anstee D.J., Rosse W., and Lublin D.M. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149 (1992) 2906-2913
23. Medof M.E., Walter E.I., Roberts W.L., Haas R., and Rosenberry T.L. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25 (1986) 6740-6747
24. Lublin D.M., Krsek-Staples J., Pangburn M.K., and Atkinson J.P. Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J. Immunol. 137 (1986) 1629-1635
25. Caras I.W., Weddell G.N., Davitz M.A., Nussenzweig V., and Martin Jr. D.W. Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science 238 (1987) 1280-1283
26. Brodbeck W.G., Liu D., Sperry J., Mold C., and Medof M.E. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156 (1996) 2528-2533
27. Finberg R.W., White W., and Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 149 (1992) 2055-2060
28. Bergelson J.M., Chan M., Solomon K.R., St. John N.F., Lin H., and Finberg R.W. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored Complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6245-6248
29. Clarkson N.A., Kaufman R., Lublin D.M., Ward T., Pipkin P.A., Minor P.D., Evans D.J., and Almond J.W. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J. Virol. 69 (1995) 5497-5501
30. Pham T., Kaul A., Hart A., Goluszko P., Moulds J., Nowicki S., Lublin D.M., and Nowicki B.J. dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli, recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. Infect. Immun. 63 (1995) 1663-1668
31. Shafren D.R., Dorahy D.J., Thorne R.F., Kinoshita T., Barry R.D., and Burns G.F. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity. J. Immunol. 160 (1998) 2318-2323
32. Lea S. Interactions of CD55 with non-complement ligands. Biochem. Soc. Trans. 30 (2002) 1014-1019
33. Hamann J., Vogel B., van Schijndel G.M., and van Lier R.A. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med. 184 (1996) 1185-1189
34. Harris C.L., Rushmere N.K., and Morgan B.P. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem. J. 341 Pt 3 (1999) 821-829
35. Miyata T., Yamada N., Iida Y., Nishimura J., Takeda J., Kitani T., and Kinoshita T. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 330 (1994) 249-255
36. Rosse W.F. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 76 (1997) 63-93
37. Tarkowski A., Trollmo C., Seifert P.S., and Hansson G.K. Expression of decay-accelerating factor on synovial lining cells in inflammatory and degenerative arthritides. Rheumatol. Int. 12 (1992) 201-205
38. Venneker G.T., van den Hoogen F.H., Boerbooms A.M., Bos J.D., and Asghar S.S. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab. Invest. 70 (1994) 830-835
39. Uesu T., Mizuno M., Inoue H., Tomoda J., and Tsuji T. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab. Invest. 72 (1995) 587-591
40. Asghar S.S. Membrane regulators of complement activation and their aberrant expression in disease. Lab. Invest. 72 (1995) 254-271
41. Inaba T., Mizuno M., Ohya S., Kawada M., Uesu T., Nasu J., Takeuchi K., Nakagawa M., Okada H., Fujita T., and Tsuji T. Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC). Clin. Exp. Immunol. 112 (1998) 237-241
42. Sasaki M., Joh T., Tada T., Okada N., Yokoyama Y., and Itoh M. Altered expression of membrane inhibitors of complement in human gastric epithelium during helicobacter-associated gastritis. Histopathology 33 (1998) 554-560
43. Hamann J., Wishaupt J.O., van Lier R.A., Smeets T.J., Breedveld F.C., and Tak P.P. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42 (1999) 650-658
44. Dalmasso A.P. The complement system in xenotransplantation. Immunopharmacology 24 (1992) 149-160
45. Zaidi A., Bhatti F., Schmoeckel M., Cozzi E., Chavez G., Wallwork J., White D., and Friend P. Kidneys from HDAF transgenic pigs are physiologically compatible with primates. Transplant. Proc. 30 (1998) 2465-2466
46. Asghar S.S., and Pasch M.C. Therapeutic inhibition of the complement system. Y2K update. Front Biosci. 5 (2000) E63-E81
47. Bjorge L., Hakulinen J., Wahlstrom T., Matre R., and Meri S. Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer 70 (1997) 14-25
48. Hara T., Kojima A., Fukuda H., Masaoka T., Fukumori Y., Matsumoto M., and Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br. J. Haematol. 82 (1992) 368-373
49. Koretz K., Bruderlein S., Henne C., and Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br. J. Cancer 66 (1992) 810-814
50. Inoue H., Mizuno M., Uesu T., Ueki T., and Tsuji T. Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer. Acta Med. Okayama 48 (1994) 271-277
51. Yamakawa M., Yamada K., Tsuge T., Ohrui H., Ogata T., Dobashi M., and Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73 (1994) 2808-2817
52. Mäenpää A., Junnikkala S., Hakulinen J., Timonen T., and Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148 (1996) 1139-1152
53. Niehans G.A., Cherwitz D.L., Staley N.A., Knapp D.J., and Dalmasso A.P. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149 (1996) 129-142
54. Simpson K.L., Jones A., Norman S., and Holmes C.H. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am. J. Pathol. 151 (1997) 1455-1467
55. Varsano S., Rashkovsky L., Shapiro H., Ophir D., and Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 113 (1998) 173-182
56. Guc D., Canpinar H., Kucukaksu C., and Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur. J. Haematol. 64 (2000) 3-9
57. Nakagawa M., Mizuno M., Kawada M., Uesu T., Nasu J., Takeuchi K., Okada H., Endo Y., Fujita T., and Tsuji T. Polymorphic expression of decay-accelerating factor in human colorectal cancer. J. Gastroenterol. Hepatol. 16 (2001) 184-189
58. Mustafa T., Klonisch T., Hombach-Klonisch S., Kehlen A., Schmutzler C., Koehrle J., Gimm O., Dralle H., and Hoang-Vu C. Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int. J. Oncol. 24 (2004) 285-294
59. Hosch S.B., Scheunemann P., Luth M., Inndorf S., Stoecklein N.H., Erbersdobler A., Rehders A., Gundlach M., Knoefel W.T., and Izbicki J.R. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. J. Gastrointest. Surg. 5 (2001) 673-679
60. Nasu J., Mizuno M., Uesu T., Takeuchi K., Inaba T., Ohya S., Kawada M., Shimo K., Okada H., Fujita T., and Tsuji T. Cytokine-stimulated release of decay-Accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin. Exp. Immunol. 113 (1998) 379-385
61. Li L., Spendlove I., Morgan J., and Durrant L.G. CD55 is over-expressed in the tumour environment. Br. J. Cancer 84 (2001) 80-86
62. Loberg R.D., Day L.L., Dunn R., Kalikin L.M., and Pienta K.J. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8 (2006) 69-78
63. Terui Y., Sakurai T., Mishima Y., Mishima Y., Sugimura N., Sasaoka C., Kojima K., Yokoyama M., Mizunuma N., Takahashi S., Ito Y., and Hatake K. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97 (2006) 72-79
64. Sasaki M., Joh T., Tada T., Okada N., Yokoyama Y., and Itoh M. Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter-associated gastritis. Histopathology 33 (1998) 554-560
65. Nightingale T.E., and Gruber J. Helicobacter and human cancer. J. Natl. Cancer Inst. 86 (1994) 1505-1509
66. Okuda K., Kanamaru A., Ueda E., Kitani T., Okada N., Okada H., Kakishita E., and Nagai K. Expression of decay-accelerating factor on hematopoietic progenitors and their progeny cells grown in cultures with fractionated bone marrow cells from normal individuals and patients with paroxysmal nocturnal hemoglobinuria. Exp. Hematol. 18 (1990) 1132-1136
67. Nakagawa M., Mizuno M., Kawada M., Uesu T., Nasu J., Takeuchi K., Okada H., Endo Y., Fujita T., and Tsuji T. Polymorphic expression of decay-accelerating factor in human colorectal cancer. J. Gastroenterol. Hepatol. 16 (2001) 184-189
68. Jones J., and Morgan B.P. Apoptosis is associated with reduced expression of complement regulatory molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology 86 (1995) 651-660
69. Hensel F., Hermann R., Schubert C., Abe N., Schmidt K., Franke A., Shevchenko A., Mann M., Müller-Hermelink H.K., and Vollmers H.P. Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 59 (1999) 5299-5306
70. Hensel F., Hermann R., Brandlein S., Krenn V., Schmausser B., Geis S., Müller-Hermelink H.K., and Vollmers H.P. Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab. Invest. 81 (2001) 1553-1563
71. Packham G., and Cleveland J.L. c-Myc and apoptosis. Biochim. Biophys. Acta 1242 (1995) 11-28
72. Steinert M., Wobus M., Boltze C., Schutz A., Wahlbuhl M., Hamann J., and Aust G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 161 (2002) 1657-1667
73. Nasu J., Mizuno M., Uesu T., Takeuchi K., Inaba T., Ohya S., Kawada M., Shimo K., Okada H., Fujita T., and Tsuji T. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin. Exp. Immunol. 113 (1998) 379-385
74. Brandt B., Mikesch J.H., Simon R., Rötger A., Kemming D., Schier K., Sauter G., and Bürger H. Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. Biochem. Biophys. Res. Commun. 329 (2005) 318-323
75. Andoh A., Fujiyama Y., Sumiyoshi K., Sakumoto H., and Bamba T. Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Gastroenterology 111 (1996) 911-918
76. Varsano S., Rashkovsky L., Shapiro H., and Radnay J. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am. J. Respir. Cell. Mol. Biol. 19 (1998) 522-529
77. Takeuchi K., Mizuno M., Uesu T., Nasu J., Kawada M., Hori S., Okada H., Endo Y., Fujita T., and Tsuji T. Epidermal growth factor induces expression of decay-accelerating factor in human colonic cancer cells via the mitogen-activated protein kinase pathway. J. Lab. Clin. Med. 138 (2001) 186-192
78. Holla V.R., Wang D., Brown J.R., Mann J.R., Katkuri S., and DuBois R.N. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J. Biol. Chem. 280 (2005) 476-483
79. Mason J.C., Yarwood H., Sugars K., Morgan B.P., Davies K.A., and Haskard D.O. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 94 (1999) 1673-1682
80. Schmitt C.A., Schwaeble W., Wittig B.M., Meyer zum Buschenfelde K.H., and Dippold W.G. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur. J. Cancer 35 (1999) 117-124
81. Spiller O.B., Criado-Garcia O., Rodriguez De Cordoba S., and Morgan B.P. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121 (2000) 234-241
82. Lidington E.A., Haskard D.O., and Mason J.C. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 96 (2000) 2784-2792
83. Mason J.C., Lidington E.A., Ahmad S.R., and Haskard D.O. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am. J. Physiol. Cell. Physiol. 282 (2002) C578-C587
84. Mason J.C., Lidington E.A., Yarwood H., Lublin D.M., and Haskard D.O. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum. 44 (2001) 138-150
85. Chen S., Caragine T., Cheung N.K., and Tomlinson S. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res. 60 (2000) 3013-3018
86. Cheung N.K., Walter E.I., Smith-Mensah W.H., Ratnoff W.D., Tykocinski M.L., and Medof M.E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81 (1988) 1122-1128
87. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., and Kirschfink M. Complement resistance of tumor cells: basal and induced Mechanisms. Mol. Immunol. 36 (1999) 929-939
88. Jurianz K., Ziegler S., Donin N., Reiter Y., Fishelson Z., and Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 93 (2001) 848-854
89. Kuraya M., Yefenof E., Klein G., and Klein E. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol. 22 (1992) 1871-1876
90. Azuma A., Yamano Y., Yoshimura A., Hibino T., Nishida T., Yagita H., Okumura K., Seya T., Kannagi R., Shibuya M., et al. Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins. Scand. J. Immunol. 42 (1995) 202-208
91. Harris C.L., and Morgan B.P. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology 86 (1995) 311-318
92. Zhong R.K., Kozii R., and Ball E.D. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor. Br. J. Haematol. 91 (1995) 269-274
93. Varsano S., Rashkovsky L., Shapiro H., Ophir D., and Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 113 (1998) 173-182
94. Magyarlaki T., Mosolits S., Baranyay F., and Buzogany I. Immunohistochemistry of complement response on human renal cell carcinoma biopsies. Tumori 82 (1996) 473-479
95. Whitlow M.B., and Klein L.M. Response of SCC-12F, a human squamous cell carcinoma cell line, to complement attack. J. Invest. Dermatol. 109 (1997) 39-45
96. Blok V.T., Daha M.R., Tijsma O., Harris C.L., Morgan B.P., Fleuren G.J., and Gorter A. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J. Immunol. 160 (1998) 3437-3443
97. Gelderman K.A., Blok V.T., Fleuren G.J., and Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab. Invest. 82 (2002) 483-493
98. King P.D., Batchelor A.H., Lawlor P., and Katz D.R. The role of CD44, CD45, CD45RO, CD46 and CD55 as potential anti-adhesion molecules involved in the binding of human tonsillar T cells to phorbol 12-myristate 13-acetate-differentiated U-937 cells. Eur. J. Immunol. 20 (1990) 363-368
99. Kusama T., Miyagawa S., Moritan T., Kubo T., Yamada M., Sata H., Fukuta D., Matsunami K., and Shirakura R. Downregulation of NK cell-mediated swine endothelial cell lysis by DAF (CD55). Transplant. Proc. 35 (2003) 529-530
100. Perussia B., Trichieri G., Jackson A., Warner N., Faust J., Rumpold H., Kraft D., and Lanier L.L. The Fc receptor for IgG on human natural killer cells: phenotypic, fuctional and comparative studies with monoclonal antibodies. J. Immunol. 133 (1984) 180-189
101. Nicholson-Weller A., Russian D., and Austen K.F. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay-accelerating factor (DAF). J. Immunol. 137 (1986) 1275-1279
102. Lawrence D.W., Bruyninckx W.J., Louis N.A., Lublin D.M., Stahl G.L., Parkos C.A., and Colgan S.P. Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia. J. Exp. Med. 198 (2003) 999-1010
103. Davis L.S., Patel S.S., Atkinson J.P., and Lipsky P.E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 141 (1988) 2246-2252
104. Shibuya K., Abe T., and Fujita T. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J. Immunol. 149 (1992) 1758-1762
105. Shenoy-Scaria A.M., Kwong J., Fujita T., Olszowy M.W., Shaw A.S., and Lublin D.M. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J. Immunol. 149 (1992) 3535-3541
106. Tosello A.C., Mary F., Amiot M., Bernard A., and Mary D. Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J. Inflamm. 48 (1998) 13-27
107. Stefanova I., Horejsi V., Ansotegui I.J., Knapp W., and Stockinger H. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 254 (1991) 1016-1019
108. Parolini I., Sargiacomo M., Lisanti M.P., and Peschle C. Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Blood 87 (1996) 3783-3794
109. Robinson P.J., and Spencer S.C. Phosphatidylinositol-anchored membrane proteins and lymphocyte activation. Immunol. Lett. 19 (1988) 85-93
110. Uhlemann A.C., Brenner B., Gulbins E., Linderkamp O., and Lang F. Stimulation of TK1 lymphoma cells via alpha 4 beta 7 integrin results in activation of src-tyrosine-and MAP-kinases. Biochem. Biophys. Res. Commun. 239 (1997) 68-73
111. Mahabeleshwar G.H., Das R., and Kundu G.C. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 279 (2004) 9733-9742
112. Robinson P.J., Millrain M., Antoniou J., Simpson E., and Mellor A.L. A glycophospholipid anchor is required for Qa-2-mediated T cell activation. Nature 342 (1989) 85-87
113. Su B., Waneck G.L., Flavell R.A., and Bothwell A.L. The glycosyl-phosphatidylinositol anchor is critical for Ly-6A/E-mediated T cell activation. J. Cell. Biol. 112 (1991) 377-384
114. Robinson P.J. Signal transduction by GPI-anchored membrane proteins. Cell. Biol. Int. Rep. 15 (1991) 761-767
115. Cinek T., and Horejsi V. The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. J. Immunol. 149 (1992) 2262-2270
116. Stefanova I., and Horejsi V. Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J. Immunol. 147 (1991) 1587-1592
117. Kuraya M., and Fujita T. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55). Int. Immunol. 10 (1998) 473-480
118. Hamann J., Stortelers C., Kiss-Toth E., Vogel B., Eichler W., and van Lier R.A. Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur. J. Immunol. 28 (1998) 1701-1707
119. McNight A.J., and Gordon S. The EGF-TM7 family: unusual structures at the leukocyte surface. J. Leukoc. Biol. 63 (1998) 271-280
120. Hamann J., Eichler W., Hamann D., Kerstens H.M., Poddighe P.J., Hoovers J.M., Hartmann E., Strauss M., and van Lier R.A. Expression cloning and chromosomal mapping of the leukocyte antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J. Immunol. 155 (1995) 1942-1950
121. Gray J.X., Haino M., Roth M.J., Maguire J.E., Jensen P.N., Yarme A., Stetler-Stevenson M.A., Siebenlist U., and Kelly K. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J. Immunol. (1996) 5438-5447
122. Leemans J.C., te Velde A.A., Florquin S., Bennink R.J., de Bruin K., van Lier R.A., van der Poll T., and Hamann J. The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J. Immunol. 172 (2004) 1125-1131
123. Visser L., de Vos A.F., Hamann J., Melief M.J., van Meurs M., van Lier R.A., Laman J.D., and Hintzen R.Q. Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J. Neuroimmunol. 132 (2002) 156-163
124. Inoue T., Yamakawa M., and Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol. Pathol. 55 (2002) 193-199
125. Liu Y., Chen L., Peng S.Y., Chen Z.X., and Hoang-Vu C. Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J. Zhejiang Univ. Sci. 6 (2005) 913-918
126. Aust G., Eichler W., Laue S., Lehmann I., Heldin N.E., Lotz O., Scherbaum W.A., Dralle H., and Hoang-Vu C. CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res. 57 (1997) 1798-1806
127. Hoang-Vu C., Bull K., Schwarz I., Krause G., Schmutzler C., Aust G., Kohrle J., and Dralle H. Regulation of CD97 protein in thyroid carcinoma. J. Clin. Endocrinol. Metab. 84 (1999) 1104-1109
128. Aust G., Steinert M., Schutz A., Boltze C., Wahlbuhl M., Hamann J., and Wobus M. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am. J. Clin. Pathol. 118 (2002) 699-707
129. Steinert M., Wobus M., Boltze C., Schutz A., Wahlbuhl M., Hamann J., and Aust G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 161 (2002) 1657-1667
130. Mustafa T., Eckert A., Klonisch T., Kehlen A., Maurer P., Klintschar M., Erhuma M., Zschoyan R., Gimm O., Dralle H., Schubert J., and Hoang-Vu C. Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 108-119
131. Wang T., Ward Y., Tian L., Lake R., Guedez L., Stetler-Stevenson W.G., and Kelly K. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105 (2005) 2836-2844
132. Wobus M., Vogel B., Schmucking E., Hamann J., and Aust G. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int. J. Cancer 112 (2004) 815-822
133. Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., and Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 52 (2003) 638-642
134. Mizuno M., Nakagawa M., Uesu T., Inoue H., Inaba T., Ueki T., Nasu J., Okada H., Fujita T., and Tsuji T. Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. Gastroenterology 109 (1995) 826-831
135. Iwagaki N., Mizuno M., Nasu J., Okazaki H., Hori S., Yamamoto K., Okada H., Tsuji T., Fujita T., and Shiratori Y. Advances in the development of a reliable assay for the measurement of stool decay-accelerating factor in the detection of colorectal cancer. J. Immunoassay Immunochem. 23 (2002) 497-507
136. Ohya S., Mizuno M., Kawada M., Nasu J., Okada H., Shimomura H., Yamamoto K., Fujita T., and Tsuji T. Improvements in the measurement of stool decay-Accelerating factor in the detection of colorectal cancer. Acta Med. Okayama 56 (2002) 171-176
137. Kawada M., Mizuno M., Nasu J., Uesu T., Okazaki H., Okada H., Shimomura H., Yamamoto K., Tsuji T., Fujita T., and Shiratori Y. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J. Lab. Clin. Med. 142 (2003) 306-312
138. Mizuno M., Iwagaki N., Nasu J., Okazaki H., Yamamoto K., Okada H., Tsuji T., Fujita T., and Shiratori Y. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. Am. J. Gastroenterol. 98 (2003) 2550-2555
139. Spendlove I., Li L., Carmichael J., and Durrant L.G. Decay accelerating factor (CD55): a target for cancer vaccines?. Cancer Res. 59 (1999) 2282-2286
140. Vollmers H.P., O'Connor R., Muller J., Kirchner T., and Müller-Hermelink H.K. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res. 49 (1989) 2471-2476
141. Vollmers H.P., Dammrich J., Ribbert H., Wozniak E., and Müller-Hermelink H.K. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76 (1995) 550-558
142. Vollmers H.P., Dammrich J., Hensel F., Ribbert H., Meyer-Bahlburg A., Ufken-Gaul T., von Korff M., and Müller-Hermelink H.K. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 79 (1997) 433-440
143. Vollmers H.P., Hensel F., Hermann R., Dammrich J., Wozniak E., Gessner P., Herrmann B., Zimmermann U., and Müller-Hermelink H.K. Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol. Rep. 5 (1998) 35-40
144. Vollmers H.P., Timmermann W., Hensel F., Illert B., Thiede A., and Müller-Hermelink H.K. Adjuvant immunotherapy of stomach carcinoma with antibody-induced apoptosis. Zentralbl. Chir. 125 Suppl. 1 (2000) 37-40
145. Illert B., Otto C., Vollmers H.P., Hensel F., Thiede A., and Timmermann W. Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol. Rep. 13 (2005) 765-770
146. Fishelson Z., Donin N., Zell S., Schultz S., and Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40 (2003) 109-123
147. Hsu Y.T., Mohanty S., Litvinchuk A., and Hou Q. Generation and characterization of monoclonal antibodies directed against the surface antigens of cervical cancer cells. Hybrid. Hybridomics 23 (2004) 121-125
148. Ziller F., Macor P., Bulla R., Sblattero D., Marzari R., and Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35 (2005) 2175-2183
149. Pritchard-Jones K., Spendlove I., Wilton C., Whelan J., Weeden S., Lewis I., Hale J., Douglas C., Pagonis C., Campbell B., Alvarez P., Halbert G., and Durrant L.G. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer 92 (2005) 1358-1365
150. Agrez M.V., Shafren D.R., Gu X., Cox K., Sheppard D., and Barry R.D. Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells. Virology 239 (1997) 71-77
151. Shafren D.R., Williams D.T., and Barry R.D. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J. Virol. 71 (1997) 9844-9848
152. Shafren D.R., Au G.G., Nguyen T., Newcombe N.G., Haley E.S., Beagley L., Johansson E.S., Hersey P., and Barry R.D. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10 (2004) 53-60
153. Au G.G., Lindberg A.M., Barry R.D., and Shafren D.R. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol. 26 (2005) 1471-1476